YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Sandoz launches as an independent entity on the SIX Swiss Exchange, equipped with a robust credit profile and a bright growth trajectory in the generics and biosimilars industry.
Dawn of a New Era
The separation from former parent company Novartis marks a new era for Sandoz, the global leader in generic and biosimilar medicines. Chairman Gilbert Ghostine emphasized that while the company is independent, its purpose remains unchanged: pioneering access to quality medicines for patients worldwide, Korea Bizwire reported.
According to the Sandoz website, CEO Richard Saynor outlined six strategic levers driving the company's long-term value during the Sandoz Capital Markets Day. These include capitalizing on market fundamentals, maintaining leadership and scale, pursuing multiple growth drivers, improving margins, accelerating cash generation, and nurturing a compelling sustainability story.
Unwavering Commitment to Pioneering Access
Sandoz actively shapes the global healthcare environment by delivering significant annual savings of over USD 17 billion in Europe and the US alone. With a strong presence in over 100 countries, the company reaches approximately 500 million patients annually, generating an estimated total social impact of USD 180 billion annually.
As an independent company, Sandoz is fully enabled to execute its purpose-driven strategy. Focused on sustainable leadership within the generics and biosimilars industry, Sandoz is poised to make an even greater impact on global healthcare systems.
Accelerating Profitable Growth
Sandoz is well-positioned for continued profitable growth with its inclusion in market indices and investment-grade credit rating. The company's commitment to innovation, quality, and accessibility ensures its role as a global leader and European champion in the generic and biosimilar medicines sector.
Sandoz's dedication to making quality medicines available to more people in more places exemplifies its pursuit of novel delivery methods. By leveraging technology and innovation, the company aims to expand access and address unmet healthcare needs on a global scale.
Generics and biosimilars account for an estimated 80% of medicines used worldwide by volume, at about 25% of the total cost. Despite strong competitive pressures, the industry is set to grow steadily over the next decade, driven by underlying demand for these system-critical medicines.
Photo: Online Marketing/Unsplash
